IP Library Granted Patent US 7,595,387
Granted Patent B2
US 7,595,387 · App. 11/019,831 · Granted Sep 29, 2009

Modified polynucleotides for reducing off-target effects in RNA interference

Assignees: Dharmacon, Inc.; Merck & Co., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,595,387
App. No.
11/019,831
Granted
Sep 29, 2009
Kind
B2
Abstract

Methods and compositions for performing RNA interference with decreased off-target effects are provided The methods and compositions permit effective and efficient applications of RNA interference to applications such as diagnostics and therapeutics through the use of modifications to the siRNA. Uniquely modified siRNAs have been developed that reduce off-target effects incurred in gene-silencing. The modifications comprise 2′-O-alkyl or mismatch modification(s) at specific positions on the sense and/or antisense strands.

Claims (24)

1. A double stranded polyribonucleotide comprising:

a. a sense strand comprising a sense region, wherein said sense region comprises:

i. a first 5′ sense nucleotide, wherein said first 5′ sense nucleotide comprises a first 2′-O-alkyl modification, and

ii. a second 5′ sense nucleotide, wherein said second 5′ sense nucleotide comprises a second 2′-O-alkyl modification; and

b. an antisense strand comprising an antisense region, wherein said antisense region comprises:

i. a first 5′ antisense nucleotide, wherein said first 5′ antisense nucleotide is phosphorylated, and

ii. a second 5′ antisense nucleotide, wherein said second 5′ antisense nucleotide comprises a third 2′-O-alkyl modification,

wherein said sense region and said antisense region are capable of forming a duplex of 18-24 base pairs of nucleotides that has at least 80% complementarity over the range of the duplex, and within said duplex said first 5′ sense nucleotide is the 5′ most nucleotide of the sense strand, said second 5′ sense nucleotide is immediately adjacent to and downstream of the first 5′ sense nucleotide, said first 5′ antisense nucleotide is the 5′ most nucleotide of the antisense strand and said second 5′ antisense nucleotide is immediately adjacent to and downstream of the first 5′ antisense nucleotide, wherein all nucleotides of each strand of said double stranded polyribonucleotide other than said first 5′ sense nucleotide, said second 5′ sense nucleotide, and said second 5′ antisense nucleotide comprises a 2′-OH, and wherein said antisense strand is capable of silencing a target gene with reduced off-target gene silencing.

2. The double stranded polyribonucleotide of claim 1 , wherein said first 2′-O-alkyl modification comprises 2′-O-methyl, said second 2′-O-alkyl modification comprises 2′-O-methyl, and said third 2′-O-alkyl modification comprises 2′-O-methyl.

3. The double stranded polyribonucleotide of claim 1 , wherein the double stranded polyribonucleotide comprises a 3′ overhang, and said 3′ overhang is 1 to 6 bases on at least one of said sense strand or said antisense strand.

4. The double stranded polyribonucleotide of claim 1 , wherein said first 2′-O-alkyl modification, second 2′-O-alkyl modification, and third 2′-O-alkyl modification are independently selected from the group consisting of 2′-O- ethyl, 2′-O-propyl, 2′-O-isopropyl, 2′-O-butyl, 2′-O-isobutyl, 2′-O-ethyl-O-methyl, and 2′-O-ethyl-OH.

5. The double stranded polyribonucleotide of claim 1 , wherein only said first 5′ antisense nucleotide is phosphorylated.

6. The double stranded polyribonucleotide of claim 3 , wherein said 3′ overhang is 2 bases on at least one of said sense strand or said antisense strand.

7. The double stranded polyribonucleotide of claim 1 , wherein said double stranded polyribonucleotide has reduced off-target gene silencing activity compared to a double stranded polyribonucleotide having the same nucleotide sequence as said double stranded polyribonucleotide, but does not contain 2′-O-alkyl modifications in said sense and antisense strands.

8. The double stranded polyribonucleotide of claim 1 , wherein said double stranded polyribonucleotide has reduced off-target gene silencing activity compared to a double stranded polyribonucleotide having the same nucleotide sequence as said double stranded polyribonucleotide, but does not contain 2′-O-alkyl modifications in said antisense strand.

9. A double stranded polyribonucleotide comprising:

a. a sense strand comprising a sense region, wherein said sense region comprises:

i. a first 5′ sense nucleotide, wherein said first 5′ sense nucleotide comprises a first 2′-O-methyl modification, and

ii. a second 5′ sense nucleotide, wherein said second 5′ sense nucleotide comprises a second 2′-O-methyl modification; and

b. an antisense strand comprising an antisense region, wherein said antisense region comprises:

i. a first 5′ antisense nucleotide, wherein said first 5′ antisense nucleotide is phosphorylated, and

ii. a second 5′ antisense nucleotide, wherein said second 5′ antisense nucleotide comprises a third 2′-O-methyl modification,

wherein said sense region and said antisense region are capable of forming a duplex of 19 base pairs of nucleotides that has at least 80% complementarity over the range of the duplex, and within said duplex said first 5′ sense nucleotide is the 5′ most nucleotide of the sense strand, said second 5′ sense nucleotide is immediately adjacent to and downstream of the first 5′ sense nucleotide, said first 5′ antisense nucleotide is the 5′ most nucleotide of the antisense strand and said second 5′ antisense nucleotide is immediately adjacent to and downstream of the first 5′ antisense nucleotide, wherein all nucleotides of each strand of said double stranded polyribonucleotide other than said first 5′ sense nucleotide, said second 5′ sense nucleotide, and said second 5′ antisense nucleotide comprises a 2′-OH, wherein the double stranded polyribonucleotide comprises an overhang of two nucleotides at the 3′ termini of both said sense strand and said antisense strand and wherein said antisense strand is capable of silencing a target gene with reduced off-target gene silencing.

10. The double stranded polyribonucleotide of claim 9 , wherein said duplex of 19 base pairs of nucleotides has 100% complementarity over the range of the duplex and the two nucleotides of said overhangs at the 3′ termini of the sense strand and the antisense strand are UU.

Assignments (6)
CHANGE OF NAME Recorded Oct 2, 2017
From: GE HEALTHCARE DHARMACON, INC.
To: DHARMACON, INC.
Reel/Frame 044105/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2014
From: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
To: GE HEALTHCARE DHARMACON, INC.
Reel/Frame 032863/0603 →
CHANGE OF NAME Recorded Apr 15, 2014
From: DHARMACON, INC.
To: THERMO FISHER SCIENTIFIC BIOSCIENCES INC.
Reel/Frame 032689/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2009
From: ROSETTA INPHARMATICS LLC
To: MERCK & CO., INC.
Reel/Frame 022954/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2007
From: LINSLEY, PETER S.
To: ROSETTA INPHARMATICS LLC
Reel/Frame 019772/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2006
From: LEAKE, DEVIN; FEDOROV, YURIY; REYNOLDS, ANGELA; KHVOROVA, ANASTASIA; MARSHALL, WILLIAM
To: DHARMACON, INC.
Reel/Frame 017568/0501 →
Continuity (3)
Continuation In Part PCTUS200401034300 · Apr 1, 2004
Provisional Application 6063022800 · Nov 22, 2004
Related Publication 20050223427A1 · Oct 6, 2005